TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2321776

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine-0.0002% fentanyl
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 63
Study: 395627

Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl PGE2 (PG) 50 micrograms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl PGE2 (PG) 100 micrograms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pamine (methscopolamine bromide) 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of PG 50 micrograms and Pamine 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of PG 100 micrograms and Pamine 2.5 mg
Number of subjects: 11
Study: 31162101

Group type: EXPERIMENTAL
Intervention: Atezolizumab with cobimetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab without cobimetinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 0
Study: 27865590

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (100 units of Botox)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (distal pancreatectomy without botulinum toxin injection)
Number of subjects: 29
Study: 25956209

Group type: EXPERIMENTAL
Intervention: panitumumab + FOLFOX4
Number of subjects: 505

Group type: COMPARATOR
Intervention: Resection
Number of subjects: 505

Group type: COMPARATOR
Intervention: Complete resection
Number of subjects: 505
Study: 23377388

Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White petroleum jelly
Number of subjects: 0
Study: 20225606

Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)-based therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 100
Study: 18493166

Group type: EXPERIMENTAL
Intervention: Hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 50
Study: 16841199

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 12722035

Group type: EXPERIMENTAL
Intervention: Parallel dual dialyzers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Series dual dialyzers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dual dialyzers (parallel and series)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dual-dialyzer therapy
Number of subjects: 18
Study: 10870722

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (3 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (3 mg)
Number of subjects: 75
Study: 8528039

Group type: EXPERIMENTAL
Intervention: Active 22 mg nicotine patches
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 357
Study: 1675119

Group type: EXPERIMENTAL
Intervention: morphine (3 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: fentanyl (75 micrograms)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sufentanil (50 micrograms)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: buprenorphine (0.3 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: oxymorphone (1 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: saline
Number of subjects: 90
Study: 6114885

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31923073

Group type: EXPERIMENTAL
Intervention: Surgery (perineorrhaphy and distal posterior colporrhaphy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Physical therapy (pelvic floor muscle therapy)
Number of subjects: 70
Study: 31694979

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (2 mg for 8-15 kg; 4 mg for >15 kg)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 918
Study: 28733430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11984

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 11984

Group type: EXPERIMENTAL
Intervention: On-statin levels of the smallest VLDL particle subclass
Number of subjects: 11984

Group type: EXPERIMENTAL
Intervention: Inclusion of key VLDL measures during statin therapy
Number of subjects: 11984
Study: 26340483

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Plus (CP+) group prenatal care
Number of subjects: 24
Study: 23424061

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS), 5 daily sessions
Number of subjects: 0
Study: 21321680

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Balloon defecation training
Number of subjects: 65
Study: 19840477

Group type: EXPERIMENTAL
Intervention: hiBM+PBSCT (Group A)
Number of subjects: 125

Group type: COMPARATOR
Intervention: hiBMT (Group B)
Number of subjects: 125
Study: 17967547

Group type: EXPERIMENTAL
Intervention: Active extension without upper arm fixation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active flexion without upper arm fixation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active extension with upper arm fixation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active flexion with upper arm fixation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Passive flexion with upper arm fixation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active flexion with upper arm retroflexion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active range of motion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Passive range of motion
Number of subjects: 42
Study: 15376398

Group type: EXPERIMENTAL
Intervention: Jia Wei Si Jun Zi Tang (JWSJZT) + regular protective therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Regular protective therapy
Number of subjects: 65
Study: 11846301

Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide (IE- containing regimen)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vincristine and melphalan (VM-containing regimen)
Number of subjects: 128
Study: 9771863

Group type: EXPERIMENTAL
Intervention: High-protein diet (2.1 g/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-protein diet (0.7 g/kg)
Number of subjects: 7
Study: 7844437

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study: 2843320

Group type: EXPERIMENTAL
Intervention: HERPCHEK test
Number of subjects: 180

Group type: COMPARATOR
Intervention: Virus culture
Number of subjects: 180
Study: 31668666

Group type: EXPERIMENTAL
Intervention: Intraosseous dexamethasone injection (4 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone injection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both techniques of dexamethasone injection
Number of subjects: 27
Study: 30314509

Group type: EXPERIMENTAL
Intervention: Young SMILES
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 27668695

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg with rosuvastatin 20 mg for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg alone for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg with fimasartan 120 mg for 7 days
Number of subjects: 0
Study: 26655452

Group type: EXPERIMENTAL
Intervention: Junior Master Gardner (JMG) intervention
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Walk Across Texas (WAT) intervention
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Postintervention weight status
Number of subjects: 44
Study: 24033250

Group type: EXPERIMENTAL
Intervention: BI 2536 (day 1 schedule)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BI 2536 (days 1 + 8 schedule)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BI 2536 (day 1-3 schedule)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: BI 2536 (all schedules)
Number of subjects: 68
Study: 21359646

Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 8101

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once daily for 10 ± 4 days
Number of subjects: 8101
Study: 18434751

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 17145229

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12698145

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (group 1)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional coronary surgery (group 2)
Number of subjects: 200
Study: 10709776

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole (≥ 200 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Number of subjects: 0
Study: 9180111

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 328
Study: 8243909

Group type: EXPERIMENTAL
Intervention: Pamphlet and videotaped presentation on common childhood illnesses
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 246
Study: 3895411

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30295231

Group type: EXPERIMENTAL
Intervention: Home-based maternal nutritional counselling from trained community health volunteers
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Routine antenatal care (Control)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Home-based maternal nutritional counselling
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Maternal height <154.5 cm
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Last antenatal care visits at 1st or 2nd trimesters
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Pre-term delivery
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Maternal mid-upper arm circumference <23 cm
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 1001
Study: 29464843

Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (MTAs) with positive prediction based on Functional Annotation for Cancer Treatment (FACT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (MTAs) with negative prediction based on Functional Annotation for Cancer Treatment (FACT)
Number of subjects: 12
Study: 26913786

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 133
Study: 25419594

Group type: EXPERIMENTAL
Intervention: Total bilirubin (TB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum bile acids (SBA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of TB and SBA
Number of subjects: 0
Study: 22618925

Group type: EXPERIMENTAL
Intervention: Guideline-based multicomponent intervention
Number of subjects: 4449

Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 4449
Study: 20584032

Group type: EXPERIMENTAL
Intervention: RMMI
Number of subjects: 30
Study: 16926854

Group type: EXPERIMENTAL
Intervention: Plasmakinetic resection of the prostate (PRP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 240
Study: 16372777

Group type: EXPERIMENTAL
Intervention: Razors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clippers
Number of subjects: 0
Study: 12020338

Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA(1c) level of 7.3%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (HbA(1c) level of 9.1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 9794057

Group type: EXPERIMENTAL
Intervention: Early intervention program
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study: 8567141

Group type: EXPERIMENTAL
Intervention: Ultrasonographic monitoring of preoperative chemotherapy
Number of subjects: 15
Study: 2560470

Group type: EXPERIMENTAL
Intervention: CY 216 (7,500 anti-Xa units I.C. daily subcutaneous injection)
Number of subjects: 4498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4498

Group type: EXPERIMENTAL
Intervention: CY 216
Number of subjects: 4498
Study: 31668787

Group type: EXPERIMENTAL
Intervention: Remifentanil (Group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol (Group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (Group N)
Number of subjects: 60
Study: 30151913

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 66

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 66
Study: 28234826

Group type: EXPERIMENTAL
Intervention: Anatomical silicone device
Number of subjects: 75

Group type: COMPARATOR
Intervention: Round silicone implant
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both anatomical and round implants
Number of subjects: 75
Study: 26634569

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA; 3 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline (CTR)
Number of subjects: 40
Study: 23461421

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 0
Study: 21150631

Group type: EXPERIMENTAL
Intervention: Caudal clonidine 1 μg kg⁻¹ with 0.25% bupivacaine (0.75 ml kg⁻¹)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caudal clonidine 0.75 μg kg⁻¹ with 0.25% bupivacaine (0.75 ml kg⁻¹)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (0.75 ml kg⁻¹) alone
Number of subjects: 90
Study: 18458907

Group type: EXPERIMENTAL
Intervention: Gustatory stimulation with 5 cc of lemon juice
Number of subjects: 19
Study: 16882326

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg b.i.d.), Amoxicillin (1 g b.i.d.), Esomeprazole (20 mg b.i.d.) for 10 days (group A(1) and A(2))
Number of subjects: 163

Group type: COMPARATOR
Intervention: Empirical treatment with Levofloxacin, Amoxicillin, and Esomeprazole at the same dose and duration (group B(1) and B(2))
Number of subjects: 163
Study: 12631184

Group type: EXPERIMENTAL
Intervention: W-CPC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CPC-W
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CPC-TP
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TP-CPC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: W-TP
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TP-W
Number of subjects: 21

Group type: COMPARATOR
Intervention: W-W
Number of subjects: 21
Study: 10960839

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 11811

Group type: COMPARATOR
Intervention: DRE screening
Number of subjects: 11811
Study: 8925110

Group type: EXPERIMENTAL
Intervention: ABO incompatibility cases (26 cases)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Alloantibodies cases (35 cases)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Long-term follow-up of all cases
Number of subjects: 61
Study: 1616472

Group type: EXPERIMENTAL
Intervention: Pain subjects (musicians with upper limb pain)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pain-free controls (musicians without upper limb pain)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (pain subjects and pain-free controls)
Number of subjects: 28
Study: 6507309

Group type: EXPERIMENTAL
Intervention: Pindolol (small dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pindolol (large dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol (small dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol (large dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31778451

Group type: EXPERIMENTAL
Intervention: Agroforestry systems with Schizolobium parahyba in Intercrop-I
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Agroforestry systems with Parapiptadenia rigida in Intercrop-I
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Agroforestry systems with non-deciduous trees (higher crown shading)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Wheat monoculture (no tree species present)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Harvest management techniques (with and without harvesting of the forage species)
Number of subjects: 7
Study: 30103399

Group type: EXPERIMENTAL
Intervention: Multi-component telemonitoring intervention (self-measurements of nutritional outcomes and physical activity, education, and follow-up by a nurse)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Multi-component telemonitoring intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 214
Study: 26755091

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 20
Study: 24717460

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement < 7.1 hours
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 7.1 to < 17.6 hours
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 17.6 to < 46.0 hours
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 46.0 hours
Number of subjects: 439
Study: 21952978

Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg twice a day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice a day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg twice a day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 20200757

Group type: EXPERIMENTAL
Intervention: PFOS concentrations
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: PFOA concentrations
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (primiparous women)
Number of subjects: 1400
Study: 17012266

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 198
Study: 14624915

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 10989239

Group type: EXPERIMENTAL
Intervention: Lumbar spine BMD greater than 1.20 g/cm(2) (or 2.5 S.D. above the mean)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Each 0.1 g/cm(2) increase in lumbar spine BMD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Each 0.1 g/cm(2) increase in femoral neck BMD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Estrogen therapy in osteoporotic women
Number of subjects: 150
Study: 9411906

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amitriptyline 10 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amitriptyline 100 mg
Number of subjects: 85
Study: 1428304

Group type: COMPARATOR
Intervention: Cyclobenzaprine (C) 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine (C) 10 mg plus Ibuprofen (I) 600 mg
Number of subjects: 32
Study: 3935458

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulpiride (25 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg and 100 mg i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31757206

Group type: EXPERIMENTAL
Intervention: Doxapram 50 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 110
Study: 29134633

Group type: EXPERIMENTAL
Intervention: AZD1419 (inhaled TLR9 agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27035595

Group type: COMPARATOR
Intervention: Black coffee (175 ml)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Coffee with 20% milk (175 ml)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Coffee with 50% milk (175 ml)
Number of subjects: 32
Study: 24472665

Group type: EXPERIMENTAL
Intervention: Thawed plasma stored at 1-6 °C for 5 days
Number of subjects: 30
Study: 22359099

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-electrolyte solution (PEG)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 116
Study: 21147688

Group type: EXPERIMENTAL
Intervention: Odanacatib 5 mg daily for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Zoledronic acid (ZA) 4 mg I.V. once at study initiation
Number of subjects: 43